Use of the human tumor stem cell assay (HTSCA) to prospectively select patients for phase I and II clinical trials of bisantrene (BIS)

D. S. Alberts, C. Mackel, S. E. Salmon

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Use of the human tumor stem cell assay (HTSCA) to prospectively select patients for phase I and II clinical trials of bisantrene (BIS)'. Together they form a unique fingerprint.